SG Americas Securities’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

SG Americas Securities’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,331	Closed	-$118K	–	3936
2017 Q3	$118K	Buy	10,331 +644	+7%	+$6.77K	﹤0.01%	3072
2017 Q2	$95K	Buy	9,687 +6,322	+188%	+$129K	﹤0.01%	2936
2017 Q1	$82K	Sell	3,365 -4,667	-58%	-$117K	﹤0.01%	3039
2016 Q4	$258K	Buy	8,032 +5,498	+217%	+$234K	﹤0.01%	2166
2016 Q3	$127K	Buy	+2,534	New	+$105K	﹤0.01%	2873
2015 Q3	–	Sell	-1,303	Closed	-$127K	–	2949
2015 Q2	$127K	Sell	1,303 -863	-40%	-$82.1K	﹤0.01%	2222
2015 Q1	$202K	Buy	2,166 +356	+20%	+$30.3K	﹤0.01%	1874
2014 Q4	$161K	Buy	+1,810	New	+$132K	﹤0.01%	2598
2014 Q2	–	Sell	-1,694	Closed	-$67K	–	2827
2014 Q1	$67K	Buy	+1,694	New	+$72.5K	﹤0.01%	2282
2013 Q4	–	Sell	-2,330	Closed	-$70K	–	3240
2013 Q3	$70K	Buy	+2,330	New	+$81.5K	﹤0.01%	2743

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SG Americas Securities's MACK Position: Q4 2017 in Review

SG Americas Securities sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 10,331 shares — an estimated $118K sold.

SG Americas Securities first reported a position in MACK in Q3 2013 and held it in 10 quarters. The position peaked at $258K in Q4 2016. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

SG Americas Securities reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
SG Americas Securities sold 10,331 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $118K.
SG Americas Securities first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 10 quarters.
SG Americas Securities's Merrimack Pharmaceuticals, Inc. position peaked at $258K in Q4 2016.
78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on SG Americas Securities's 13F filing for Q4 2017, filed 24 Jan 2018.